Selected publications

1. Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, Kelly GL, Herold MJ. Humanized MCL-1 mice enable accurate pre-clinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018 Oct 11;132(15):1573-1583. doi: 10.1182/blood-2018-06-859405 PMID: 30139826
2. Salvamoser R, Brinkmann K, O’Reilly LA, Whitehead L, Strasser A, Herold MJ. Characterisation of mice lacking the inflammatory caspases-1/-11/-12 reveals no contribution of caspase-12 to cell death and sepsis. Cell Death Diff (2018) Cell Death Differ. 2018 Aug 28. doi: 10.1038/s41418-018-0188-2 PMID: 30154447
3. Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, Mizutani S, Brennan MS, Schenk RL, Lindqvist LM, Papenfuss AT, O’Connor L, Strasser A, Herold MJ. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med. 2018 Jul;24(7):947-953. doi: 10.1038/s41591-018-0043-5 PMID: 29892060
4. Schenk RL, Tuzlak S, Carrington E, Zhan Y, Heinzel S, Teh CE, Gray DHD, Tai L, Lew A, Villunger A, Strasser A, Herold MJ. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ. 2017 Mar;24(3):534-545. PMID: 28085150
5. Tuzlak  S, Schenk R, Vasanthakumar A, Preston S, Haschka MD, Zotos D, Kallies A, Strasser A, Villunger A, Herold MJ. The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis upon viral infection. Cell Death Differ. 2017 Mar;24(3):523-533. PMID: 28085151
6. Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DCS, Fairlie WD, Strasser A, Herold MJ.  Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Cell Death Differ. 2016 23 12 2054-2062. PMID: 27689874
7. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dukorno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Grave F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016. 538 7626 477-482. PMID: 27760111
8. Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, Wilcox S, Tai L, Strasser A, Herold MJ. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep, 2015. 10(8):1422-32. PMID: 25732831
9. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, Lee EF, Lindstrom MS, Wiman KG, Huang DC, Bouillet P, Rowe M, Rickinson AB, Herold MJ*, Strasser A*. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014 Jan 1;28(1):58-70. PMID: 24395247
10. Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, Ploner A, Reichardt HM, Villunger A, Herold MJ. Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood. 2012 Jun 21;119(25):6032-42. PMID: 22581448

* Joint senior author

More publications